Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.
Veterinary Pharmaceuticals Market Set To Climb From $37.01 Billion In 2026 To $46.88 Billion By 2030
The veterinary pharmaceuticals market has experienced robust growth in recent years. It is projected to expand from $34.92 billion in 2025 to $37.01 billion in 2026, at a compound annual growth rate (CAGR) of 6.0%. The historical growth of this market can be attributed to factors like the increasing prevalence of animal diseases, a rising livestock population, an increase in companion animals, supportive government regulations for animal health, and progress in veterinary research.
The veterinary pharmaceuticals market size is projected to experience substantial expansion in the coming years. This market is set to reach $46.88 billion in 2030, exhibiting a compound annual growth rate (CAGR) of 6.1%. Factors contributing to this anticipated growth involve the emergence of biopharmaceutical innovations, increased research and development efforts in veterinary medicines, the adoption of precision medicine for animals, a rise in preventive veterinary healthcare, and growing investments in companion animal pharmaceuticals. Significant developments expected during this forecast period encompass the creation of new veterinary medications, the expansion of companion animal healthcare, an increase in the application of combination therapies, the broader availability of oral and topical formulations, and a focus on swift metabolism and bioavailability.
Get A Free Sample Report With In-Depth Market Insights:
Veterinary Pharmaceuticals Market Expansion Drivers: What’s Shaping Future Growth?
The veterinary pharmaceuticals market is anticipated to experience growth due to the increasing trend of pet ownership. Pet ownership refers to the legal and ethical responsibility undertaken by individuals or households for the care, maintenance, and well-being of domesticated animals. The rise in pet ownership is largely attributed to people seeking companionship and emotional support. A greater number of pets drives an increased need for veterinary care, which consequently stimulates the expansion of veterinary pharmaceuticals by broadening the market for medications, vaccines, and preventive treatments crucial for maintaining the health of a larger and more diverse companion animal population. For instance, in April 2025, according to the Canadian Animal Health Institute, a Canada-based trade association, in 2024, Canada was home to an estimated 7.2 million dogs and 8.2 million cats, making pets an integral part of more than half of Canadian households. Therefore, increasing pet ownership is a primary driver for the growth of the veterinary pharmaceuticals market.
Veterinary Pharmaceuticals Market Segment Performance And Emerging Opportunities
The veterinary pharmaceuticals market covered in this report is segmented –
1) By Type: Veterinary Vaccines, Veterinary Antibiotics, Veterinary Parasiticides, Other Types
2) By Type Of Animal: Livestock, Companion Animals
3) By Type Of Vaccine: Inactivated Vaccines, Attenuated Vaccines, Recombinant Vaccines, Other Type Of Vaccines
4) By Route Of Administration: Oral, Parenteral, Topical, Other Routes Of Administrations
5) By End User: Veterinary Hospitals, Veterinary Clinics, Pharmacies And Drug Stores
Subsegments:
1) By Veterinary Vaccines: Inactivated Vaccines, Live Attenuated Vaccines, Recombinant Vaccines, DNA Vaccines, Subunit Vaccines
2) By Veterinary Antibiotics: Penicillins, Cephalosporins, Tetracyclines, Fluoroquinolones, Macrolides
3) By Veterinary Parasiticides: Endoparasiticides, Ectoparasiticides, Endectocides, Antiprotozoals
4) By Other Types: Anti-Inflammatory Drugs, Analgesics, Hormonal Medications, Antifungals
Veterinary Pharmaceuticals Market Strategic Trends: What Defines The Next Growth Phase?
Key companies operating in the veterinary pharmaceuticals market are focusing on developing new offerings, including molidustat oral suspensions, to attract a larger customer base, boost sales, and increase their earnings. Molidustat oral suspension is a medicine specifically used for addressing nonregenerative anemia associated with chronic kidney disease (CKD) in cats. For example, in September 2023, Elanco Animal Health Incorporated, a pharmaceutical company from the US, introduced Varenzin-CA1 (molidustat oral suspension). This product is notable as the first and only medication available for managing non-regenerative anemia in cats with chronic kidney disease (CKD), and it received provisional approval from the U.S. Food and Drug Administration (FDA). Varenzin-CA1 offers the distinct advantage of being an innovative, needle-free oral suspension solution for cats, allowing it to be given at home without the necessity of in-clinic injections. This also represents the first medication for cats to achieve expanded conditional approval, a regulatory route designed to encourage the creation of new treatments and broaden the available options for animals facing unusual conditions, severe or life-threatening illnesses, or diseases for which no effective or readily available treatments currently exist.
Veterinary Pharmaceuticals Market Company Landscape And Competitive Strategy
Major companies operating in the veterinary pharmaceuticals market are Zoetis Inc, Merck & Co. Inc, Boehringer Ingelheim International Gmb, Elanco Animal Health Incorporated, Ceva Sante Animale, Virbac SA, Dechra Pharmaceuticals PLC, Vetoquinol S.A., Phibro Animal Health Corporation, Kyoritsu Seiyaku Corporation, Hebei Chengshengtang Animal Pharmaceutical, Shijiazhuang Fengqiang Animal Pharmaceutical Co .Ltd, Vvaan Lifesciences Private Limited, Century Pharmaceuticals Limited, Cargill India Pvt. Ltd., Jurox Pty Ltd, Bayer, Veteq, Nimrod Veterinary Products Ltd., Bimeda, Orion Animal Health, Petmedix, Eco Animal Health, Teknofarma, Farmavet, Candioli Pharma, Suanfarma, Marino Ibericamed, MPA veterinary, Swetrade Pharmaceuticals AB, Animalcare, VET-AGRO Sp. z o. o, CANPOLAND SA, Cymedica, VIC Group, NITA-FARM, Apicenna LLC, Delos Medica, Provet Group, Bioveta AS, Veterinarski Zavod Subotica, PharmaGal s.r.o., Trifecta Pharmaceuticals USA LLC., Alberta Veterinary Laboratories Ltd., Veterinary Purchasing Co. Ltd, UCBVET, Syntec, Sauvet, Vetanco, Chemo Argentina, Brouwer, Agrovet Market Animal Health, Lemavet, Primo Veterinary Medicines Trading LLC., AL Kubara Veterinary Medicines Trading LLC., Eurovets Veterinary Suppliers, Saudi Pharmaceutical Industries, DBK Pharma S.A.E., Dawa Limited, Neimeth International Pharmaceuticals, Osy-Adamu Pharmaceutical Co., Global Vet (U) Ltd.
View The Full Veterinary Pharmaceuticals Market Report:
Veterinary Pharmaceuticals Market Largest Region: Which Geography Holds The Biggest Share?
North America was the largest region in the veterinary pharmaceuticals market in 2025. Asia-Pacific was the second-largest region in the global veterinary pharmaceuticals market report. The regions covered in the veterinary pharmaceuticals market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model








